CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer

Malumbres Marcos

首页> 外文期刊>Cancer Cell >CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer

【24h】

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer

机译：CDK4 / 6抑制剂恢复HER2（+）乳腺癌中的治疗敏感性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.

机译：CDK4 / 6抑制剂已获得治疗激素阳性乳腺肿瘤的批准，但其他侵袭性癌症是否尚不清楚。在这个癌细胞，Goel等人的问题中。（2016）报告CDK4 / 6抑制剂在减少MTOR函数中的意外活动，并将HER2阳性癌患者重新敏感到EGFR / HER2封锁中。

著录项

来源
《Cancer Cell》 |2016年第3期|共2页
作者
Malumbres Marcos;
展开▼
作者单位

Ctr Nacl Invest Oncol Cell Div &

Canc Grp Melchor Fernandez Almagro 3 E-28029 Madrid Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer [J] . Malumbres Marcos Cancer Cell . 2016,第3期

机译：CDK4 / 6抑制剂恢复HER2（+）乳腺癌中的治疗敏感性
2. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors [J] . Goel Shom, Wang Qi, Watt April C., Cancer Cell . 2016,第3期

机译：用CDK4 / 6抑制剂克服HER2阳性乳腺癌的治疗耐药性。
3. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer [J] . Migliaccio Ilenia, Bonechi Martina, McCartney Amelia, Cancer Treatment Reviews . 2021,第1期

机译：CDK4 / 6抑制剂：重点是响应的生物标志物和激素受体阳性HER2阴性乳腺癌的治疗后治疗策略
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Targeting Her2-Positive Breast Cancer Metabolism Through Dietary and Pharmacological Interventions to Improve Therapeutic Efficacy [D] . Rainey, Magdalena A. 2019

机译：通过饮食和药理学干预靶向Her2阳性乳腺癌的代谢，以提高治疗效果
6. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors [O] . Shom Goel, Qi Wang, April C. Watt, -1

机译：用CDK4 / 6抑制剂克服HER2阳性乳腺癌的治疗耐药性。
7. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors [O] . Rebecca Burne, Sanjeev Balu, Annie Guérin, 2021

机译：HR + / HER2-先进乳腺癌患者的医疗资源利用率和成本比较与其他CDK4 / 6抑制剂进行治疗

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2(+) Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅